List of Therapeutic Companies in Michigan - 30

BAMF Health is the world's first vertically integrated platform for molecular imaging and radiopharmaceutical therapy. Using the most advanced imaging and therapy technologies, BAMF Health is dedicated to providing comprehensive and intelligent treatment options for patients with serious health issues such as cancer, heart disease, and stroke.

Becker Orthopedic was founded in 1933 by Otto K. Becker to provide high quality orthotic components and central fabrication services. Today, Becker Orthopedic remains a family business dedicated to quality, service, and innovation in the field of orthotics.

BlueWillow Biologics® is developing and enabling a new generation of safe and effective nasal vaccines to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. Our novel intranasal NanoVax® adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. We are a clinical-stage company advancing a pipeline of proprietary programs including Peanut Allergy, HSV-2, Covid-19, Anthrax, Pandemic Flu and RSV.

CircNova, Inc. is a biotechnology company that leverages our unique AI NovaEngine™ to generate, analyze and identify circular RNA for therapeutic development.

Corium is a commercial-stage biopharmaceutical company that is leading the development and commercialization of central nervous system (CNS) healthcare therapies that provide clinicians with important treatment options for patients, their families, and their caregivers. Collaborating with some of the world's largest pharmaceutical and consumer product companies, we have a track record and depth of experience in taking products from concept, through development, to manufacturing and final commercialization.

Diapin Therapeutics is a clinical-stage drug development company developing novel therapeutics for the treatment of cardiovascular and metabolic diseases. The company is focused on peptide-based therapies for diabetes and has announced groundbreaking results from the latest study of their compound DT-109, a novel oral tripeptide that inhibits NASH progression in non-human primates. Diapin Therapeutics is also known for its tripeptide Diapin, which effectively lowers blood glucose levels in male patients. The company has an option agreement with the University of Michigan to commercialize peptide-based therapies for cardiovascular and metabolic diseases.

Official LinkedIn page for Esperion. At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc. Community guidelines: https://bit.ly/3vLCGdO Certified Great Place To Work®

EVOQ Therapeutics is developing immunotherapies to improve the lives of individuals fighting autoimmune diseases. There are more than 100 chronic autoimmune diseases - many severely debilitating, and some life-threatening. According to the National Institutes of Health, up to 23.5 million Americans (over 7% of the population) suffer from autoimmune disease, and the prevalence is rising. Autoimmune disease occurs when the body’s central immune tolerance system fails - resulting in T and B cell-mediated destruction of self-tissues. This immune system failure is responsible for many devastating diseases including – Type 1 Diabetes, Celiac disease, Multiple sclerosis and Rheumatoid Arthritis. EVOQ’s technology unleashes and restores the body’s natural immune tolerance pathways.

Small Molecules, Contract Manufacturing

HAPPE is an emerging leader of next generation orthopaedic and spinal implants enabled by the HAPPE™ (HydroxyApatite Porous PolyEtheretherketone) platform. The HAPPE material platform offers interconnected, cancellous porosity with exposed hydroxyapatite on pore surfaces to enable robust bone in-growth and on-growth confirmed in preclinical testing.

HistoSonics is a venture-backed medical device start-up company developing a non-invasive sonic beam therapy platform and procedure using the science of histotripsy. Histotripsy utilizes the pressure created by focused sound energy to liquify and destroy targeted tissue, including diseased tissue and tumors, at sub-cellular levels. The company's new platform delivers personalized, tissue specific treatments with precision and control, and without the undesirable side effects of many of today's interventional and surgical modalities. HistoSonics is led by a team of experienced domain experts and industry leaders with offices in Ann Arbor, Michigan and Minneapolis, MN.

Iaso Therapeutics, Inc. is a start-up company spun out from Michigan State University. The company was founded in 2018 by Dr. Xuefei Huang. Dr. Huang is a MSU Foundation Professor jointly appointed in the Department of Chemistry and the Department of Biomedical Engineering, Michigan State University. In addition, he is a member of the newly formed Institute for Quantitative Health Science & Engineering. With over 25 years of experience, his research program is focused on the development of novel technologies for next generation vaccines, including vaccines targeting both cancer and infectious diseases. Iaso Therapeutics, Inc. aims to translate the cutting-edge technologies developed in the Huang laboratory to promote human health and treat diseases.

Innovative BioTherapies (IBT) is a small biotechnology company located in Ann Arbor, MI, focused on developing medical devices to solve unmet medical needs.

Developing novel serpin-based therapies for the treatment of fibrosis and fibroproliferative disorders.

Our NEUROGENX Team is proud to abundantly equip and enable providers to deliver a higher standard of care to patients suffering various balance issues, neuropathy and other chronic nerve conditions. At the heart of our partnership is a philosophy in which we invest fully in our providers as partners and hold ourselves accountable and pledge our commitment. A commitment to ensure our partners both clinical and business success. We have built our NEUROGENX Solutions Program on this: (1) Support & Service (2) Performance & Results (3) Model Training & Continuous Coaching to Ensure Clinical & Business Success within the first months, throughout the first year and years to come. We recognize conscientious and enterprising providers have different needs as well as different visions about practice growth. For these reasons, we have multiple steps and pathways for procuring and implementing NEUROGENX Clinical and Business Solution Assets to create a custom fit to suit every enterprising style and budget. We're committed to work with you to customize a combination of technologies, training and support systems to attain your perfect fit!

Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing innovative small molecule therapies for eye disorders. The company aims to address unmet medical needs in the ocular space, particularly in retinal and refractive disorders. Ocuphire Pharma offers research and development services to create novel treatments for various eye conditions. The company collaborates with pharmaceutical partners to advance its drug candidates through clinical trials and commercialization. Its product pipeline includes Nyxol, an ophthalmic solution for dim light and night vision disturbances; APX3330, an oral inhibitor for diabetic retinopathy and macular edema; APX2009, aimed at treating wet age-related macular degeneration; and Phentolamine Ophthalmic Solution (RYZUMVI), approved for pharmacologically induced mydriasis and under development for other conditions.

ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to helping patients see the future. Our mission is to develop innovative therapeutics to protect and improve the vision of patients with a range of retinal disease and conditions. By advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the natural Fas pathway, ONL is pioneering an entirely new approach to preserve sight. It is the first and only company focused on preventing Fas-mediated death of key retinal cells, which is a root cause of vision loss, a leading cause of blindness and an unaddressed medical need. ONL’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide Fas inhibitor designed to protect retinal cells from both death and inflammatory signaling pathways. ONL1204 Ophthalmic Solution is being developed for the treatment of retinal detachment, an acute condition for which the company has been granted orphan drug designation by the FDA. In addition, the company is currently developing ONL1204 in geographic atrophy associated with age-related macular degeneration, glaucoma, and other acute and chronic indications.

Penrose TherapeuTx is a U.S.-based pharmaceutical company focused on developing innovative small-molecule therapies for the treatment of advanced cancers. The company also develops small-molecule therapies to treat cancer and has prominent researchers and leaders in the field as part of its scientific advisory board and executive team.

Chemotherapy is the foundation of cancer treatment because it is so effective, but it is also the downfall of cancer treatment because it is so toxic. Patients can experience hair loss, nausea, fatigue, aching, or neuropathy and often find that the treatment seems worse than the disease. Imagine the impact a technology would have on cancer treatment if that technology maintains or even improves the efficacy of established chemotherapies without the harmful side effects. And that is what Peptinovo aims to do. Peptinovo Biopharma Inc. has invented and patented a targeted, drug-delivery platform: Peptide-Amphiphile Lipid Micelle (PALM) that reduces or eliminates chemotherapy-induced peripheral neuropathy (CIPN), one of the most serious side effects threatening treatment outcomes for world-leading chemotherapy drugs like paclitaxel. PALM delivers higher doses of proven drugs INTO tumors, keeping them AWAY from healthy tissues. Lives are extended and side effects are avoided. Peptinovo is developing its first platform, PNB-281, to eliminate the nerve damage caused by paclitaxel against many major cancers including breast, ovarian, lung, prostate, and pancreatic cancers. Nerve damage is the most serious side-effect threatening the ability to complete the cancer treatment. Peptinovo's technology can be used to treat many cancers and it can be used with many chemotherapy drugs.

We are a bioinformatics-based precision medicine platform company translating patient-specific and population-based medical big data into novel pharmacological clinical treatment decision support products and services. We offer a proprietary technology, the PredictMed Platform, designed to help clinicians and health systems optimize precision in the selection of appropriate medications, drug combinations and dosages that improve each patient's health, while also reducing adverse reactions. Our PrecīsMed platform represents a significant step forward in accurately assessing a patient’s complete medication profile. Physicians can finally see the full spectrum of medications present in the patient, and identify appropriate dosing levels for therapeutic effectiveness. PrecīsMed can accurately assess prescribing trends, medication adherence and EHR coverage, as well as define medication concentrations in patients with comorbid disorders.

Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. Rockwell’s new innovative therapy Triferic is the only FDA approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. Via dialysate during each dialysis treatment, Triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. Unlike IV iron products, Triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming Functional Iron Deficiency (FID) in ESRD patients. Visit www.triferic.com to view the Triferic mode-of-action (MOA) video and for more information. Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad, with three manufacturing/distribution facilities located in the U.S. Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell’s exclusive renal drug therapies support disease management initiatives to improve quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing costs and improving patient convenience.

SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing cancer treatment through safer drug delivery. They are based in Michigan, USA and are known for their innovative drug delivery platform SDP that engineers new therapeutics for better & broader clinical applications.

Seraph Biosciences, Inc. is a biomedical device company headquartered in Detroit, Michigan. The company was founded in 2014 with the primary purpose of commercializing its groundbreaking, diagnostic technology known as Seraspec®. Seraph's team consists of seasoned academic physicians, biomedical engineers, artificial intelligence experts, and device commercialization professionals tasked with combatting the major public health crises of our time. By leveraging the principles of Raman Spectroscopy, Seraspec® represents a paradigm shift away from current methods for screening and identification of dangerous bacterial, viral and fungal pathogens. Seraspec's® patented technology and method of detection effectively eliminates the need for time-consuming and costly laboratory-based methods of specimen collection, processing and pathogen identification. Safety, efficiency, accuracy and profitability are simultaneously enhanced through a portable, point-of-need technology for real-time pathogen detection and identification. A higher power just got involved in the fight against infection.

The simplicity of our design--born out of our extensive experience--comes down to the basic notion that traditional fixation techniques aren't strong enough and don't last. Our InSet™ approach to Glenoid fixation is revolutionizing shoulder arthroplasty and, more importantly, improving procedure longevity--ultimately changing patient's lives.

We are a clinical-stage biopharmaceutical company developing an oral small molecule for the treatment of thyroid eye disease (TED). Our team consists of highly experienced drug developers, supplemented by global experts through our Scientific Advisory Board.

Strata Oncology is a high-growth, state-of-the art, precision oncology company, delivering a new standard of care that integrates molecular profiling, decision support and clinical trial participation into routine practice. We do this by partnering with major healthcare systems across the country, who systematically send their cancer patients’ biopsies to our high-throughput CLIA lab for genomic sequencing, with results provided to the oncologist within days, indicating the tumor profile, and matches to appropriate therapies and drug trials. This accelerates the move to personalized medicine – right medicines to the right patients at the right time. Our personnel are passionate about and committed to making a positive difference, now, in the lives of cancer patients and their families. Clinicians, pathologists, bioinformaticists, software engineers, lab technicians and more, coming together to give access to those without, uncovering insight that might be hidden, all while spreading urgency to all. Experience a career that connects a fast-paced team environment with a worthy pursuit – feel good about what you’ve accomplished at the end of every day!

We are a biotechnology company dedicated to curing Alzheimer's disease. We are planning FDA-sponsored human trials, using telomerase therapy to reset cell aging within the central nervous system. We believe that Alzheimer's disease can stopped, prevented, and cured.

Tetra Therapeutics is a clinical stage biotechnology company developing a portfolio of therapeutic products. Tetra designs drugs to treat memory loss and cognitive impairment by improving how the brain processes and stores information. The company is focused on treating cognitive impairment and memory loss by improving brain function.

Tissue Regeneration Systems™ (TRS™) is a start-up medical device company commercializing a breakthrough skeletal reconstruction and bone regeneration technology platform licensed from the Universities of Michigan and Wisconsin. Our technology addresses a broad range of clinical applications, and has been validated by comprehensive University, NIH and company-sponsored research initiatives spanning a period of well over a decade. NOVEL 3D PRINTED RESORBABLE SCAFFOLDS TRS has a proven capability to fabricate complex, patient specific, load- bearing resorbable implant solutions using 3D printing methods. UNIQUE BIOACTIVE MINERAL COATING Our proprietary mineral coating, Affinity™, exhibits unique bioactive properties that can be applied to our resorbable scaffolds, as well as to conventional orthopedic and spine implants. The Affinity morphology is a plate-like nanostructure, which mimics the mineral structure of native bone, and modulates the biologic environment in a manner not previously exhibited by other implant coatings. SCALABLE FDA COMPLIANT MANUFACTURING TRS has established a fully independent, FDA-compliant manufacturing facility with a certified cleanroom. Our operation can support commercial product volumes. FDA CLEARANCE Both our 3D printed resorbable scaffold technology and our Affinity mineral coating have received FDA 510(k) clearance. STRONG INTELLECTUAL PROPERTY AND TRADE SECRET POSITION TRS has an extensive patent portfolio and has also accumulated a number of important trade secrets in perfecting our technology and fabrication methods. Together, this creates meaningful protection and exclusivity for our technology platform.

Therapeutic Systems Research Laboratories (TSRL), Inc. is a privately women-owned, pre-clinical accelerator based in Ann Arbor, Michigan focused on building companies that develop infectious disease therapeutics. A key aspect of our strategy is our Technology Accelerator, an ongoing collaborative process that lends our expertise and capabilities to entrepreneurs seeking to obtain the data and non-dilutive funding necessary to develop and/or commercialize their inventions. One focus is improving existing drug products by applying our versatile prodrug platform technologies to optimize therapy regimen for treating infectious diseases. Potential target indications include: influenza, HSV, VZV, CMV, EBV, poxvirus, HPV, Adenovirus, and RNA viruses. We currently employ ten full-time employees and a number of drug development consultants and generate annual revenues of approximately $2M from royalties and grants. Our team has broad experience in chemistry, molecular biology, biochemistry, analytical chemistry, in vivo animal model, PK/ADME, toxicology and formulation. Our research is conducted in a 7,200 sq. ft. facility of which 5,000 sq. ft. is wet lab space, with on-site analytical chemistry, formulation, cell culture equipment and in vivo testing capabilities.